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symptom). The Health Assessment Questionnaire (HAQ) was used to measure func-
tional status (scores 0–3). QoL was measured by the mental (MCS) and physical (PCS) 
component summary scores of the Short Form-8 (SF-8). Work/productivity loss was
measured by the Work Productivity and Activity Impairment (WPAI) instrument. 
Comparisons were made between patients who currently use SC biologics versus those 
who discontinued treatment. RESULTS: Of the 2,200 survey respondents (72%
female; average age  49.6years), 386 (17.5%) used SC biologics. The average dura-
tion of RA was 12.4 years, with 14% reporting severe disease. The patient-reported
mean scores were: morning stiffness 6.6, fatigue 6.8, pain 6.5, HAQ 1.6, MCS 43.9 
and PCS 36.4. Patients reported 61.0% work impairment and 59.2% impairments in 
daily activity. Patients who had discontinued SC biologic therapy (N  124, 32.1%)
reported signiﬁ cantly worse scores in morning stiffness, fatigue, pain, and PCS (all
P  0.05) versus patients currently treated with SC biologics (N  262, 67.9%). 
Patients who discontinued therapy had more work/activity loss; only activity impair-
ment was statistically signiﬁ cant (P  0.05). There was no signiﬁ cant difference in
HAQ scores between groups. CONCLUSIONS: RA patients using current SC biolog-
ics still suffer from serious impairments in symptoms, functional status, QoL, and 
work/productivity. However, patients who discontinued SC biologic therapy have sig-
niﬁ cantly worse symptom scores, physical functioning, and activity impairment com-
pared with those currently being treated. Both ﬁ ndings indicate there is still an unmet
medical need in RA patients.
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OBJECTIVES: To estimate changes in quality of life (SF36) and utility (SF6) in 
patients treated with naproxcinod, naproxen or placebo for 13 weeks, and to explore
the effect of different disease measures on utility. METHODS: SF36 was available
from 3 international ph 3 clinical trials in 2738 patients with knee or hip osteoarthritis 
comparing 2 doses of naproxcinod (375 and 750 mg bid) to naproxen (500 mg bid) 
and placebo. Efﬁ cacy was based on the pain, function and composite scales of the 
WOMAC™ osteoarthritis index. Co-morbidity measures included hypertension (HT)
which increases with NSAID therapy, body mass index (BMI) and diabetes. Changes
in SF6 and individual SF36 domains were compared between the groups using 
ANOVA and Dunett’s 2-sided test. The effect of the WOMAC™ indices, BP, BMI and 
diabetes on utility scores was explored using multiple regression analysis. RESULTS:
All SF36 subscales except mental health as well as utility changed signiﬁ cantly from 
baseline for all groups, and were correlated with changes in the WOMAC™ indices 
(p  0.001). The change in the active groups was signiﬁ cantly better than placebo for
pain and physical function (0.05), but not signiﬁ cantly different between treatments.
However, absolute changes in utility, pain, physical function and general health were
generally larger for naproxcinod 750 mg than naproxen 500 mg by around 10%.
Utility scores correlated signiﬁ cantly with WOMAC™, and patients with high BMI
and BP or diabetes had lower utility scores and worse WOMAC™ indices. Increase 
in utilities were larger for patients with 750 mg naproxcinod than for the other groups. 
CONCLUSIONS: The slightly larger utility and quality of life changes with naprox-
cinod 750 mg despite a similar effect as naproxen on WOMAC™ may be explained 
by a different side-effect proﬁ le and a neutral blood pressure effect.
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OBJECTIVES: To utilize WebTV technology as a tool to measure HRQOL in elderly
persons having Rheumatoid Arthritis (RA) in a nationally representative sample and 
to describe their socio-demographic characteristics, medication use and other treat-
ment choices. METHODS: A cross- sectional online survey research design. Random
digit dialing (RDD) survey procedures were used to draw a sample of 550 elderly 
arthritic individuals from US households across 44 states. A subsample of 79 individu-
als previously diagnosed with RA completed SF-36v2 survey, as part of a larger study.
Eight SF-36 domain scores and Physical and Mental Component Summary (PCS and
MCS) scores were computed and compared with cross-sectional norms for general US
population. RESULTS: Compared to the general population, our study sample per-
formed poorly with respect to all the SF-36 domains except mental health (MH) and 
social functioning (SF) domains. RA is more prevalent in whites (96%) and males 
reported higher scores for all the eight SF-36 domains than females. About 92% of 
the sample reported the use of at least one available OTC arthritic medication; 58% 
of the sample was taking prescription drugs, while about 53% reported having used
natural/herbal remedies for arthritis. A signiﬁ cant difference (p  0.003) was found 
between males and females with respect to only PCS scores. Age was found to correlate 
negatively (p  0.005) with PCS and MCS summary measures, particularly for indi-
viduals 70 years and older. CONCLUSIONS: WebTV is an effective survey administra-
tion tool for measuring HRQOL. As expected, elderly perform poorly on three of the
SF-36 domains (PF, RP, BP) having the most physical factor content. Prescription drug
use is fairly prevalent and use of OTC medications and other forms of treatment is 
popular in the population under study.
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OBJECTIVES: Through data analysis we will examine and identify the lifestyle factors 
that impact clinical outcomes of Rheumatoid Arthritis (RA) patients. METHODS:
Patients’ self-reported data was collected from the 2008 RA Patient Survey, an Internet 
survey of RA patients. We studied the effects of aerobic exercise (20 minutes a day 
per month), and cigarette smoking on RA patients. Sign and symptom scores for 
morning stiffness, fatigue, and pain are deﬁ ned from 0 (no symptom) to 10 (severe
symptom) within the survey. The Health Assessment Questionnaire (HAQ) was used
to measure functional status scores (0–3). Quality of life was measured by the mental 
component score (MCS) and physical component score (PCS) of the Short-Form 36
(SF-36). Productivity was measured by the Work Productivity and Activity Impairment 
(WPAI) Scale. There were no non-RA controls included in the study. RESULTS: A
total of 2048 respondents were included in the analysis 1001 patients exercised and
584 patients smoked cigarettes. The average age was 51.9 years and average RA 
duration was 11.9 years. Patients’ mean MCS and PCS scores in the exercise (40.7, 
36.7) and non-smoking groups (41.2, 34.4) were signiﬁ cantly higher, than in the non-
exercise (40.0, 31.3) and smoking groups (37.4, 32.7). Overall work and productivity
impairment was 41.5% (exercise) versus 45.4% (non-exercise), and 45.5% (smoking)
versus 42.2% (non-smoking). Signs, symptoms, and HAQ scores were signiﬁ cantly 
better in the exercise and non-smoking groups (all P  0.05). CONCLUSIONS: RA
patients who exercise regularly have higher quality of life scores and clinical outcomes. 
Those that smoke cigarettes have lower quality of life scores and higher symptom/
HAQ scores suggesting that this habit may be detrimental to their clinical outcomes.
These results suggest that these lifestyle choices inﬂ uence the overall risk of impairment 
in RA patients.
PMS43
IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN
ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?
Gooch K1, Feeny DH2, Wong R3, Pangan A1, Revicki D4, van der Heijde D5
1Abbott Laboratories, Abbott Park, IL, USA, 2Kaiser Permanente Center for Health Research, 
Portland, OR, USA, 3Abbott Laboratories, Parsippany, NJ, USA, 4United BioSource
Corporation, Bethesda, MD, USA, 5Leiden University Medical Center, Leiden, Netherlands
OBJECTIVES: QALYs are an important outcome used in cost-effectiveness analysis. 
The Health Utilities Index Mark 3 (HUI-3) is a self-reported measure covering 8 attri-
butes of health status. Our objective was to assess construct validity and responsiveness 
of HUI-3 in ankylosing spondylitis (AS). METHODS: Data were derived from the 
Adalimumab Trial Evaluating Long-Term Efﬁ cacy and Safety in AS (ATLAS). We speci-
ﬁ ed a priori hypotheses regarding the direction and magnitude of associations expected
between overall and single-attribute HUI-3 scores and other health status and quality
of life measures—SF-36, ASQOL, Bath AS Functional Index (BASFI), Bath AS Disease
Activity Index (BASDAI), and Patient’s Global Assessment (PGA). Using baseline data,
we calculated correlation coefﬁ cients and interpreted them via guidelines suggested by 
Guyatt for negligible, weak, moderate, and strong associations. Responsiveness was 
assessed by calculating standardized response means (SRMs) of HUI-3 scores from
baseline to Week 24 for patients meeting the minimum clinically important differences
(MCID) for the ASQOL (1.8). Responsiveness analysis was limited to patients with 
24-week HUI-3 scores. RESULTS: A total of 295 of the 315 patients enrolled in ATLAS 
were included in the analysis. Mean age was 43 years, 76.3% were male, and mean 
duration of AS was 11 years. Correlation coefﬁ cients between HUI-3 scores and other 
instruments conﬁ rmed 62.2% of the a priori hypothesis, with an additional 24.5% 
being under- or over-estimated by only one category. Results of responsiveness analysis 
demonstrated that there were signiﬁ cant differences in overall HUI-3 (SRM 1.13) and
most single-attribute change scores for patients whose changes were greater than the 
ASQOL MCID vs. those whose changes were MCID. CONCLUSIONS: These results 
suggest that HUI-3 constructs are related to similar constructs in other measures, as
expected. This study provides evidence of cross-sectional and longitudinal construct 
validity of the HUI-3 for deriving utility scores for AS patients.
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OBJECTIVES: We aimed to validate the multi-attribute health utility (MAHU) derived 
from the CAT-5D-QOL, a computer-adaptive instrument composed of 5 domains 
(Walking, Handling Objects, Daily Activities, Pain/Discomfort, and Feelings) in people 
with self-reported osteoarthritis (OA), and to compare it with WOMAC_HUI3, the 
utility derived from the standard disease-speciﬁ c measure in OA. METHODS: Data 
were collected from participants (age 50) who completed questionnaires CAT-5D-
QOL in two waves and WOMAC in one wave of a Canada-wide online survey. To 
assess construct validity, we used multivariable regression to examine the associations
